Condition: Hematologic Neoplasms · Sponsor: Hemanext
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.
This description comes directly from the study's public registry record.
Jill Badgasarian · (781) 301-7474 · jill.bagdasarian@hemanext.com
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06685848